Compare EVF & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | EVF | NRXS |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.3M | 78.9M |
| IPO Year | 1998 | 2023 |
| Metric | EVF | NRXS |
|---|---|---|
| Price | $4.86 | $7.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 60.2K | ★ 117.8K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $4.85 | $2.21 |
| 52 Week High | $5.58 | $9.33 |
| Indicator | EVF | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 26.73 | 71.91 |
| Support Level | $4.85 | $6.44 |
| Resistance Level | $5.03 | $7.54 |
| Average True Range (ATR) | 0.03 | 0.37 |
| MACD | -0.01 | 0.22 |
| Stochastic Oscillator | 4.17 | 80.18 |
Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).